By examining the effect of multiple targets (improving insulin sensitivity index and insulin resistance, reducing glycosylated hemoglobin, regulating abnormal lipid metabolism, reducing body mass index) in Jinlida granules, our research team will implement a randomized, double-blind, placebo-controlled, and multi-center clinical trial to investigate the efficacy and safety of intervention with Jinlida granules in metabolic syndrome with abnormal glucose metabolism. This evidence concerns the gene INS and Insulin resistance.